Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs AquaVita NextGen

Two GLP-1 desks, one scoreboard. We put ShedRx and AquaVita NextGen head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 176 · Grade C

AquaVita NextGen

Visit AquaVita NextGen Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 67 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make AquaVita NextGen a bad call — it's best for patients in az/ca/fl/tx/nv seeking medspa-backed glp-1 with a named medical director. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
36
Supply Reliability
86
71
Transparency
84
88
Access Breadth
85
62
Clinical Oversight
85
82
Track Record
86
73
ShedRxBrief Score 87 · 67AquaVita NextGen

Price, coverage & the tracker

ShedRxAquaVita NextGen
Brief Score87/100 (B+)67/100 (C)
Semaglutide$199/moFrom $375/mo (compounded)
Tirzepatide$299/moFrom $320/mo (starting dose, compounded)
CoverageNot disclosed5 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

AquaVita NextGen: New to the tracker on 1 August 2026. The published line reads From $320/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.